These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 18378269)
21. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Darpo B; Ferber G; Siegl P; Laurijssens B; Macintyre F; Toovey S; Duparc S Br J Clin Pharmacol; 2015 Oct; 80(4):706-15. PubMed ID: 25966781 [TBL] [Abstract][Full Text] [Related]
23. Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects. Kobylinski KC; Jittamala P; Hanboonkunupakarn B; Pukrittayakamee S; Pantuwatana K; Phasomkusolsil S; Davidson SA; Winterberg M; Hoglund RM; Mukaka M; van der Pluijm RW; Dondorp A; Day NPJ; White NJ; Tarning J Clin Pharmacol Ther; 2020 May; 107(5):1221-1230. PubMed ID: 31697848 [TBL] [Abstract][Full Text] [Related]
24. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy. Olafuyi O; Coleman M; Badhan RKS Biopharm Drug Dispos; 2017 Nov; 38(8):464-478. PubMed ID: 28710808 [TBL] [Abstract][Full Text] [Related]
25. Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. Wahajuddin M; Singh SP; Taneja I; Raju KS; Gayen JR; Siddiqui HH; Singh SK Drug Test Anal; 2016 Feb; 8(2):221-7. PubMed ID: 25975936 [TBL] [Abstract][Full Text] [Related]
26. Liquid chromatographic tandem mass spectrometric assay for quantification of 97/78 and its metabolite 97/63: a promising trioxane antimalarial in monkey plasma. Singh RP; Sabarinath S; Gautam N; Gupta RC; Singh SK J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):2074-80. PubMed ID: 19520624 [TBL] [Abstract][Full Text] [Related]
28. Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. Singhal P; Gaur A; Gautam A; Varshney B; Paliwal J; Batra V J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Nov; 859(1):24-9. PubMed ID: 17923446 [TBL] [Abstract][Full Text] [Related]
29. High Antimalarial Efficacy of Dihydroartemisinin-Piperaquine on the China-Myanmar Border: The Calm Before the Storm. Fairhurst RM Am J Trop Med Hyg; 2015 Sep; 93(3):436-437. PubMed ID: 26283745 [No Abstract] [Full Text] [Related]
30. Progress in the development of piperaquine combinations for the treatment of malaria. D'alessandro U Curr Opin Infect Dis; 2009 Dec; 22(6):588-92. PubMed ID: 19773652 [TBL] [Abstract][Full Text] [Related]
31. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial. Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Chinh NT; Quang NN; Thanh NX; Dai B; Geue JP; Addison RS; Travers T; Edstein MD Antimicrob Agents Chemother; 2009 Feb; 53(2):828-31. PubMed ID: 19047656 [TBL] [Abstract][Full Text] [Related]
33. Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia. Vanachayangkul P; Lon C; Spring M; Sok S; Ta-Aksorn W; Kodchakorn C; Pann ST; Chann S; Ittiverakul M; Sriwichai S; Buathong N; Kuntawunginn W; So M; Youdaline T; Milner E; Wojnarski M; Lanteri C; Manning J; Prom S; Haigney M; Cantilena L; Saunders D Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193647 [TBL] [Abstract][Full Text] [Related]
34. Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses. Haynes RK; Cheu KW; N'Da D; Coghi P; Monti D Infect Disord Drug Targets; 2013 Aug; 13(4):217-77. PubMed ID: 24304352 [TBL] [Abstract][Full Text] [Related]
35. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. Hung TY; Davis TM; Ilett KF J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):93-101. PubMed ID: 12798169 [TBL] [Abstract][Full Text] [Related]
36. Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem. Yang A; Zang M; Liu H; Fan P; Xing J Biomed Chromatogr; 2016 Aug; 30(8):1324-30. PubMed ID: 26821381 [TBL] [Abstract][Full Text] [Related]
37. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. Lindegardh N; Annerberg A; White NJ; Day NP J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Feb; 862(1-2):227-36. PubMed ID: 18191623 [TBL] [Abstract][Full Text] [Related]
38. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084 [No Abstract] [Full Text] [Related]
39. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Chotsiri P; Wattanakul T; Hoglund RM; Hanboonkunupakarn B; Pukrittayakamee S; Blessborn D; Jittamala P; White NJ; Day NPJ; Tarning J Br J Clin Pharmacol; 2017 Dec; 83(12):2752-2766. PubMed ID: 28695570 [TBL] [Abstract][Full Text] [Related]
40. Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding. Blessborn D; Kaewkhao K; Song L; White NJ; Day NPJ; Tarning J J Pharm Biomed Anal; 2017 Nov; 146():214-219. PubMed ID: 28886522 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]